Expression of modified glycoproteins and glycopeptides
US10633454B2 · kind B2 · utility
Assignee
Inventor
Key dates
| Filing date | Apr 30, 2018 |
| Grant date | Apr 28, 2020 |
| Priority date | — |
| Expiry date | Apr 30, 2038 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/41
- WIPO fieldBiotechnology
- WIPO sectorChemistry
Abstract
The present invention provides recombinant cells that contain a genetic modification to at least one mannosyl transferase gene. As a result of the modification the cells produce a glycoprotein or glycopeptide that has an N-linked glycan profile that is simplified or more easily humanized. The glycoprotein or glycopeptide can have at least 25% fewer high mannose structures on than the glycoprotein or glycopeptide produced by a reference cell. In some embodiments the modification is a deletion or disruption of a mannosyl transferase gene, which can be in an alg3 gene. Therefore, the proteins produced are more useful for the production of therapeutic glycoproteins than those produced by species having foreign or plant-like patterns of glycosylation. The invention also provides compositions of the glycoproteins or glycopeptides and methods of making them.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.